Novartis Venture Fund

Novartis Venture Fund, known internally as NVF, is the strategic venture arm of Novartis and one of the longest-running corporate venture funds in healthcare. NVF manages over $750 million in committed capital across more than 40 active portfolio companies in North America and Europe, and across nearly 30 years of history has invested in 163 life science companies, with most exits coming through IPOs, acquisitions, and FDA drug approvals. The fund operates with explicit financial-first independence from Novartis corporate strategy: it does not exist primarily to feed the Novartis pipeline, although portfolio companies obviously gain optionality with the parent. NVF invests only in therapeutics and platforms that develop them; the fund explicitly does not invest in medtech, diagnostics, or digital health.

The team is organized across offices in Cambridge, Massachusetts and Basel, Switzerland, with senior managing directors and partners drawn from biotech operating, big-pharma R&D, and dedicated venture roles. The fund prefers an active, hands-on style of investing, almost always taking a board seat at the rounds it leads and frequently co-creating companies with academic founders. Portfolio companies span small molecules, biologics, cell and gene therapy, RNA therapeutics, and platform biology, and the fund is particularly active in immunology, oncology, neuroscience, and cardiometabolic disease, the four therapy areas that align most closely with Novartis’s franchises. NVF has invested in 79 companies in the United States and 18 in Switzerland over its history, with additional positions across the UK, Germany, France, and Israel.

Check sizes typically run from $5 million at seed up to $25 million at Series B, with the capacity to follow on into later rounds. NVF will lead and co-lead, particularly at Series A, and is comfortable participating in syndicates with peer specialist therapeutics investors including Versant, Third Rock, OrbiMed, RA Capital, and Atlas Venture. The fund’s permanent capital-style structure inside Novartis gives it patience for the long timelines of therapeutics development, and its operating discipline tends to add real R&D rigor to the companies it backs.

Founders who should approach NVF are scientific founders with novel therapeutic platforms or assets at preclinical or early-clinical stages, repeat biotech operators with experienced management teams, and academic principal investigators with translational data. The fund is particularly receptive to companies that have a clear scientific differentiation and a credible path to clinical proof of concept. Founders building digital health, devices, diagnostics, healthcare services, or AI-only software with no therapeutic asset should not approach NVF; the fund’s mandate is therapeutics-only. Founders also should not assume that NVF investment requires or implies a partnership with Novartis, although portfolio companies do gain access to Novartis scientific networks and optionality on partnerships.

Entry path runs through warm introductions from academic collaborators, scientific advisors who serve on Novartis or NVF boards, and portfolio CEOs. NVF partners are active at JPMorgan Healthcare, BIO, and the major scientific conferences including ASCO, AACR, and ASH, and the team is publicly accessible at academic-translational events in Boston-Cambridge and Basel. Cold inbound through the website is read but converts at low rates without a strong scientific signal. Diligence is rigorous and includes scientific review by Novartis-affiliated experts where appropriate, typically four to eight weeks from first meeting to term sheet for novel platforms.

In a pitch, lead with the science, the unmet need, the IP estate, and the clinical development plan. NVF partners are deeply technical and will probe your translational data, your competitive positioning against existing programs and platforms in development at large pharma, and your manufacturing and regulatory strategy. Bring a credible chief medical or chief scientific officer, or a plan to recruit one, and a clear path from current data to a value-creating clinical inflection. The fund’s added value is best realized when founders take advantage of the NVF network: scientific advisors from across Novartis’s R&D organization, optionality on partnerships and licensing, and connections to peer therapeutic specialists who can co-syndicate later rounds. Founders who treat NVF as a long-term scientific partner rather than a strategic check will find the fund one of the more rigorous and useful corporate venture investors in therapeutics.